Mazdutide
A weight-loss shot already approved in China. Innovent Biologics' GLP-1 + glucagon dual agonist out of China, with strong Phase 3 data and a 2025 China approval for obesity.
Mazdutide: A weight-loss shot already approved in China. Innovent Biologics' GLP-1 + glucagon dual agonist out of China, with strong Phase 3 data and a 2025 China approval for obesity. Mazdutide is a Chinese-developed GLP-1 + glucagon dual agonist, same class as Survodutide and Retatrutide.
Mazdutide is a Chinese-developed GLP-1 + glucagon dual agonist, same class as Survodutide and Retatrutide. Approved in China in 2025 for obesity. The glucagon part adds a metabolic-rate bump on top of GLP-1's appetite suppression.
Not FDA approved. Approved in China (2025, Innovent, brand Xinermei) for obesity and type 2 diabetes. Eli Lilly holds ex-China rights (LY-3305677) and runs US development (Phase 2).
Available by prescription in China. Not yet available in the US.
Who it's for
- โUsers wanting a GLP/glucagon agonist with cleaner side effect profile than Survodutide reports
- โFollowers of Chinese metabolic-drug development
What to expect
- Week 1
Appetite drops. Mild nausea.
- Week 4
First titration step. Modest weight loss.
- Week 8
Cumulative loss tracking similar to Tirzepatide trajectory.
Looking at Mazdutide? Your next 3 steps
- 1Work out your syringe units
Vial size + BAC water turns into the exact units to draw for Mazdutide.
Open calculator โ - 2See what to stack & monitor
The companion supplements and the bloodwork worth tracking on this kind of protocol.
Bloodwork guide โ - 3Save it & ask the Coach
A free account gets you Coach questions every day, free; membership saves your stack and makes the Coach stack-aware.
Create free account โ
How it works (mechanism)
GLP-1 + glucagon dual agonist developed in China. Same dual-receptor strategy as Survodutide.
Dosing protocol
Stacks well with
Side effects
When NOT to use
- โ MTC / MEN-2 history
- โ Pancreatitis history
- โ Pregnancy / nursing
Bloodwork to monitor
- โข Lipid panel
- โข ALT/AST
- โข A1C
Common mistakes
- โข Treating it as freely available, it's only approved in China currently
- โข Titrating too fast
- โข Skipping protein during the cut
What it actually is
Mazdutide is a weekly GLP-1 and glucagon dual agonist developed by Innovent Biologics, and unlike most compounds in this section it is approved โ in China, for weight management, since 2025. It is not approved in the US or Europe. It is built on a molecule Eli Lilly originally developed and licensed on, and its trial programme was conducted largely in Chinese populations.
Same two-receptor logic as survodutide: the GLP-1 arm reduces appetite and slows gastric emptying, the glucagon arm raises energy expenditure and drives the liver to mobilise fat. Adding glucagon is what separates this class from the GLP-1-only drugs and it is also why resting heart rate rises and why liver fat is a target. The clinical programme being conducted in Chinese participants matters for interpretation, since baseline body weight and BMI distributions differ from the Western obesity trials.
Forms, and which is which
Manufacturer product with assured identity and potency, under a regulatory approval, dispensed in China.
Verdict: The only form with known contents.
It has no approval in the US or Europe, so identity, potency and sterility cannot be verified by a buyer outside China.
Verdict: Unverifiable contents outside its approved market.
Buyer reconstitutes, no identity assurance.
Verdict: Every quality risk at once.
No approved oral form.
Verdict: No approved oral form exists.
What it is claimed to do, graded
A phase 3 randomised trial in Chinese adults published in NEJM in 2025, plus the approval that followed. Solid evidence in the population studied.
Randomised double-blind trials in Diabetes Care and a 2026 Nature placebo-controlled trial support it.
The trial programme was conducted overwhelmingly in Chinese participants with lower baseline BMI than typical Western obesity trials. Assuming the same numbers elsewhere is an extrapolation, not a finding.
No head-to-head trial establishes this.
Grades describe how much human evidence exists for that specific claim, not whether it will work for you or whether it is safe.
Pros and cons
- โข Actually approved somewhere, on phase 3 evidence โ rare outside the big three
- โข Published in NEJM and Nature, so the data is scrutinised rather than press-released
- โข The glucagon arm targets liver fat in addition to appetite
- โข Weekly dosing
- โข Approved only in China; everywhere else it is an unapproved drug
- โข The evidence base is in a population whose baseline characteristics differ from Western obesity cohorts
- โข Raises resting heart rate through the glucagon arm
- โข Nausea and gastrointestinal effects are common
- โข Outside China, nothing sold can be verified
When to stop
- โข Resting heart rate climbing and staying up
- โข Severe persistent abdominal pain radiating to the back
- โข Vomiting that prevents keeping fluids down
- โข A new neck lump, hoarseness or difficulty swallowing
- โข Pregnancy
Interactions
GLP-1 lowers glucose, glucagon raises it, so the net effect is less predictable than with a GLP-1-only drug.
No added benefit, multiplied side effects.
Compounds the glucagon-driven heart rate increase.
Delayed gastric emptying alters absorption rate.
General weight-loss guidance, not a mazdutide trial finding.
Is this for you?
- โข People in China where it is an approved, prescribed medicine
- โข Anyone reading the phase 3 data to understand where the dual-agonist class is going
- โข You are outside China and want an approved medicine โ this is not approved for you
- โข Personal or family history of medullary thyroid carcinoma or MEN-2
- โข You have an arrhythmia or uncontrolled cardiovascular disease
- โข You are pregnant or nursing
The one number
Sources for the claims above
- Phase 3 once-weekly mazdutide in Chinese adults with obesity or overweight
- First approval and regulatory status
- Randomised double-blind trial in Chinese patients with type 2 diabetes
Drug & supplement interactions
- โ Insulin and sulfonylureas: dose reduction needed
- โ Glucagon arm: monitor HR
- โ Trial-only outside China, full US interaction profile not yet published
Community patterns
New to Mazdutide? Grab the starter checklist.
Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.
Numbers redacted in this preview. Members get the full answer, on their own stack.
Ask the Coach anything about Mazdutide or your own stack. This is it working.
Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.
Unlock the full Coach, from $4.99/week โFrequently asked
What is Mazdutide?+
Is Mazdutide FDA approved?+
Is Mazdutide legal?+
Is Mazdutide banned by WADA?+
Are you still natty after taking Mazdutide?+
Do doctors prescribe Mazdutide?+
What's the typical dose of Mazdutide?+
What are the side effects of Mazdutide?+
How long until Mazdutide starts working?+
What can you stack with Mazdutide?+
Where do people get Mazdutide?+
Mazdutide vs Retatrutide, which is better?+
Mazdutide vs Survodutide, which is better?+
Mazdutide vs Semaglutide, which is better?+
Common questions about Mazdutide
Head-to-head with Mazdutide
Tracked alongside Mazdutide
Same goal, different aisle โ each graded on its own evidence in the Pepdex catalog.
More in Fat Loss
Strong weight loss with a cleaner side effect profile than semaglutide. A dual agonist (GLP-1 + GIP), FDA-approved as Mounjaro / Zepbound.
The original weight-loss wave, sold as Ozempic / Wegovy. A GLP-1 agonist.
Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.
Daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide.